A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors.
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
05
06
2020
accepted:
24
08
2020
pubmed:
13
9
2020
medline:
22
6
2021
entrez:
12
9
2020
Statut:
ppublish
Résumé
Desmoid tumors (DT) are rare collagen-forming tumors that can exhibit locally aggressive patterns of behavior. The aim of this study was to evaluate the efficacy and safety of treatment of DT with single-agent oral vinorelbine. A retrospective review of patients treated with vinorelbine 90 mg orally on days 1, 8, and 15 of a 28-day cycle from January 2004 to July 2019 was performed. Response was assessed using RECIST version 1.1. Descriptive statistics were employed. A total of 29 patients were included. Response rate was 20.7% (6/29), and clinical benefit rate (response by RECIST 1.1 and/or clinical symptom improvement) was 65.5% (19/29). No patient experienced grade 3 or above toxicity. Common toxicities were grade 1-2 nausea (14/26, 48.3%), fatigue (9/26, 31.0%), and diarrhea (4/26, 13.8%). Single-agent oral vinorelbine is an effective, safe, and well-tolerated treatment for DT. It represents a new oral alternative for management of DT.
Identifiants
pubmed: 32918789
doi: 10.1002/ONCO.13516
pmc: PMC8186406
doi:
Substances chimiques
Vinblastine
5V9KLZ54CY
Vinorelbine
Q6C979R91Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2013-e2016Informations de copyright
© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Références
Chin J Cancer Res. 2017 Oct;29(5):455-462
pubmed: 29142465
Eur J Cancer. 2020 Mar;127:96-107
pubmed: 32004793
Cancer J. 2017 Mar/Apr;23(2):86-91
pubmed: 28410293
JAMA Oncol. 2019 Apr 1;5(4):567-568
pubmed: 30703188
Lancet Oncol. 2019 Sep;20(9):1263-1272
pubmed: 31331699
Cancer. 1989 Sep 15;64(6):1192-4
pubmed: 2766217
Pathology. 2014 Feb;46(2):135-40
pubmed: 24378386
Cancer Med. 2019 Sep;8(11):5047-5057
pubmed: 31301110
Acta Oncol. 2011 Apr;50(3):455-61
pubmed: 20799916